Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42 USD | +2.23% | +3.98% | -17.95% |
02:58pm | Bristol Myers: presents advances in lung cancer | CF |
Jun. 02 | Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.95% | 83.29B | |
+42.67% | 739B | |
+32.34% | 598B | |
-5.42% | 353B | |
+17.83% | 318B | |
+3.68% | 285B | |
+16.58% | 240B | |
+9.17% | 210B | |
-5.36% | 206B | |
+7.13% | 164B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol-Myers Squibb, Exelixis Say Opdivo Plus Cabometyx Continue to Show Benefits in Kidney Cancer Trial